UroGen Pharma

Company Overview

Snapshot

Founded in April 2004 by Asher Holtzer, UroGen Pharma operates with 201–500 employees. The company has raised a total of $522.2 million across 11 funding rounds and went public on NASDAQ in May 2017. In June 2024, UroGen Pharma announced the pricing of a public offering of ordinary shares and pre-funded warrants.

Business overview

UroGen Pharma is a biotech company developing novel solutions for specialty cancers and urologic diseases. The company's core technology is RTGel, a proprietary sustained-release, hydrogel-based platform designed to improve the therapeutic profiles of existing drugs by enabling longer exposure of urinary tract tissue to medications. UroGen's lead product candidates, UGN-101 (mitomycin urothelial gel, known as MitoGel) and UGN-102 (mitomycin intravesical gel, known as VesiGel), aim to treat non-muscle-invasive urothelial cancer, including low-grade upper-tract urothelial carcinoma and bladder cancer, respectively, often by non-surgical means. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, focusing on Drugs Discovery & Development and Drug Delivery.

Strategic signal

In June 2025, the U.S. FDA approved UroGen’s ZUSDURI™ (mitomycin) for intravesical solution as the first and only medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This approval, based on strong Phase 3 ENVISION trial results, signals a significant advancement in uro-oncology, providing a new non-surgical treatment option for a large patient population and positioning UroGen as a multi-product uro-oncology company.

Company Intelligence Q&A

What was the outcome of the Phase 3 UTOPIA trial for UGN-103?

In May 2026, UroGen Pharma reported a 94.5% six-month duration of response in its Phase 3 UTOPIA trial for UGN-103, advancing the drug toward potential approval for recurrent low-grade intermediate-risk NMIBC.

What was the result of the Q1 2026 earnings report for UroGen Pharma?

In May 2026, UroGen Pharma reported that ZUSDURI™ revenue more than doubled quarter-over-quarter and provided its Q1 2026 financial results, beating revenue estimates despite reporting a Q1 loss.

What was the outcome of the patent litigation relating to JELMYTO®?

In June 2026, UroGen Pharma announced an agreement resolving patent litigation relating to JELMYTO® (mitomycin) for pyelocalyceal solution.

What was the outcome of the FDA's Oncologic Drugs Advisory Committee meeting for UGN-102 in May 2025?

In May 2025, the FDA's Oncologic Drugs Advisory Committee (ODAC) narrowly voted against the benefit/risk profile of UGN-102 for recurrent LG-IR-NMIBC, a setback for UroGen as they awaited the FDA's final decision with a PDUFA date of June 13, 2025.

What was the impact of the permanent J Code for ZUSDURI™?

In January 2026, a permanent Healthcare Common Procedure Coding System Level II J Code for ZUSDURI™ became effective, streamlining billing and reimbursement processes and expanding patient access to this FDA-approved bladder cancer therapy.